Key facts
- GSK is acquiring three drug candidates for lung cancer.
- Two of the drug candidates are currently under FDA review for approval this year.
- The acquisition will grant GSK full ownership of these potential treatments.
GSK is set to acquire three drug candidates for lung cancer, with two of them currently under review by the FDA for approval this year. The acquisition will grant GSK full ownership of these potential treatments.
The two drug candidates currently under FDA review are expected to receive a decision on their approval status within the year, marking a significant step in GSK's expansion within the oncology sector.